Kodiak Sciences Inc. , today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third quarter we hosted an Investor R&D Day in New York," said Victor ...

EyePoint Pharmaceuticals' lead product, EYP-1901, shows promising phase 2 results for wet AMD and DME. Read more about EYPT ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

Dr Menon believes that lifestyle modifications are “essential in managing diabetes and preventing complications.” His ...

SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients d ...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine ...

Dossiers are also under review in multiple countries globally. About AVT06/AVT29 AVT06/AVT29 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept) 2 mg and 8 mg dose, ...

Trump Taps Matt Gaetz for Attorney General, a Provocative Move President-elect Trump plans to nominate the Florida congressman, among a flurry of personnel announcements as Republicans neared ...